PLRX

Pliant TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$2.50

+117.4% vs current

Most likely

Base case

55%

Probability

Target price

$1.20

+4.3% vs current

B-

Bear case

25%

Probability

Target price

$0.55

-52.2% vs current

AI sentiment snapshot

Latest data as of 2026-07-19

AI commentary

Cautious monitoring setup. Company materials provide modestly positive oncology and runway signals, but coverage is low, the peer set is not sufficiently comparable for standard-conviction conclusions, social/options/short-interest data are unavailable, and there is no verified post-earnings analyst revision or market-reaction evidence. The $1.15 price indicates skepticism, not validated upside.

RankAlpha Sentiment Codex - 2026-07-19

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-10-17catalystRunway reduces near-term financing pressureHigh impact

Pliant reported $172.4 million of cash, cash equivalents, and short-term investments as of March 31, 2026, with funding expected into the second half of 2028. This reduces immediate dilution pressure while the oncology pipeline develops. [#PR-EARNINGS-2026-05-12][#SEC-8K-2026-05-11]

2026-12-31eventFORTIFY enrollment and execution checkpointHigh impact

The company said the first participant was dosed in April in the Phase 1b FORTIFY trial of PLN-101095, with enrollment underway across selected oncology cohorts. Execution, tolerability, and continued enrollment are the next meaningful operating checkpoints. [#PR-EARNINGS-2026-05-12]

2027-07-19catalyst2027 FORTIFY interim data and durability testHigh impact

Interim FORTIFY data are expected in 2027. Early Phase 1 materials cited one confirmed complete response, two confirmed partial responses, and one unconfirmed partial response, but expansion-cohort replication and durability remain unproven. [#PR-EARNINGS-2026-05-12]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-19 • Updated nightlySource: Internal modelMethodology